Cargando…

Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review

The standard third-line treatment of metastatic colorectal cancer (mCRC) includes the small-molecule anti-vascular drugs (Regofenib and Fruquintinib) and the chemotherapy drug trifluridine and tipiracil hydrochloride (TAS-102). There is no standard treatment for mCRC if the third-line treatment fail...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yong, Chen, Xian, Li, Wenzhu, Ye, Yongsong, Du, Xiaohua, Sun, Shaodan, Liu, Lirong, Zhang, Haibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180844/ https://www.ncbi.nlm.nih.gov/pubmed/34109130 http://dx.doi.org/10.3389/fonc.2021.684309

Ejemplares similares

Current concepts of anti-EGFR targeting in metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2022)

Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer
por: Chu, Jinjin, et al.
Publicado: (2022)

Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy
por: Yang, Wentao, et al.
Publicado: (2022)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2023)

Corrigendum: Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy
por: Yang, Wentao, et al.
Publicado: (2022)

Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer
por: Qiu, Tianzhu, et al.
Publicado: (2018)

Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma
por: Xu, Weiran, et al.
Publicado: (2022)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)

Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
por: Chen, Datian, et al.
Publicado: (2019)

Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies
por: Wang, Lei, et al.
Publicado: (2020)

Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer
por: Sagawa, Tamotsu, et al.
Publicado: (2023)

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer
por: Lieu, Christopher H., et al.
Publicado: (2013)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
por: Parisi, Alessandro, et al.
Publicado: (2021)

Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer
por: Knebel, Franciele H., et al.
Publicado: (2019)

The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China
por: Ma, Yue, et al.
Publicado: (2023)

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer
por: Yan, Xin, et al.
Publicado: (2020)

Successful Treatment of pMMR MSS IVB Colorectal Cancer Using Anti-VEGF and Anti-PD-1 Therapy in Combination of Gut Microbiota Transplantation: A Case Report
por: Cheng, Xianshuo, et al.
Publicado: (2023)

Utility of dual-layer spectral-detector CT imaging for predicting pathological tumor stages and histologic grades of colorectal adenocarcinoma
por: Chen, Weicui, et al.
Publicado: (2022)

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2023)

Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review
por: Dai, Congxin, et al.
Publicado: (2021)

Anti–PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment
por: Hua, Yonghong, et al.
Publicado: (2022)

Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature
por: HOPIRTEAN, CLAUDIU, et al.
Publicado: (2018)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
por: Parisi, Alessandro, et al.
Publicado: (2020)

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
por: Saif, Muhammad Wasif
Publicado: (2013)

Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer
por: Schiffmann, Lars Mortimer, et al.
Publicado: (2018)

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
por: Yasui, H., et al.
Publicado: (2023)

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
por: Di Fiore, F, et al.
Publicado: (2010)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition
por: Ottaiano, Alessandro, et al.
Publicado: (2013)

Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies
por: Nakatsumi, Hiroshi, et al.
Publicado: (2022)

Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients
por: Salvatore, Lisa, et al.
Publicado: (2023)

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
por: Liu, X., et al.
Publicado: (2015)

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
por: Zhou, Jing, et al.
Publicado: (2021)

Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion
por: Acencio, Milena Marques Pagliarelli, et al.
Publicado: (2017)

Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_v35vm19fs8d5h7l9ijg34h53nb